- Current report filing (8-K)

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

---

 

FORM 8-K

 

---

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):    October 2, 2009

BIOSTAR PHARMACEUTICALS, INC.

 (Exact name of registrant as specified in its charter)

Maryland (State or other jurisdiction of incorporation)

333-147363 ( Commission  File Number)

20-5101287 (IRS Employer Identification No.)

No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People’s Republic of China  (Address of principal executive offices)

712046 (Zip Code)

Registrant’s telephone number, including area code: 86-029-33686638

Copies to:

Benjamin Tan, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32 Floor

New York, New York 10006

Phone: [phone]

Fax: [phone]

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

r Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

r Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

r Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

r Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

 

Item 8.01.

Other Events

 

On October 2, 2009, Biostar Pharmaceuticals, Inc. issued a press release annexed hereto as Exhibit 99.1 hereto.

The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or incorporated subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01.	Financial Statements and Exhibits.
(d)	Exhibits
	99.1           Press Release,  October 2, 2009, issued by Biostar Pharmaceuticals, Inc.

 

 

---

 

 

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSTAR PHARMACEUTICALS, INC.

Dated: October 6, 2009

By:    /s/ Elaine Zhao                                            

Name: Elaine Zhao

Title:   Chief Financial Officer

 

 

 

---